Litcius/Paper detail

Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality

F. Cannata, Mauro Chiarito, Bernhard Reimers, Elena Azzolini, Giuseppe Ferrante, Ilaria My, Giacomo Viggiani, Cristina Panico, Damiano Regazzoli, Michele Ciccarelli, Antonio Voza, Alessio Aghemo, Hongliang Li, Yibin Wang, Gianluigi Condorelli, Giulio Stefanini

2020European Heart Journal - Cardiovascular Pharmacotherapy65 citationsDOIOpen Access PDF

Abstract

Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality

Topics & Concepts

DiscontinuationAngiotensin Receptor BlockersBlood pressureMedicineCoronavirus disease 2019 (COVID-19)Internal medicineAngiotensin-converting enzymeAngiotensin IIPharmacologyCardiologyDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesVitamin C and Antioxidants ResearchLong-Term Effects of COVID-19
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality | Litcius